The global IgA nephropathy market is expected to garner a market value of US$ 41.24 Billion in 2023 and is expected to accumulate a market value of US$ 85 Billion by registering a CAGR of 7.5% in the forecast period 2023 to 2033. The growth of the IgA nephropathy market can be attributed to the growing prevalence of kidney diseases amongst different age groups. The market for IgA nephropathy registered a CAGR of 4.8% in the historical period 2017 to 2022
IgAN is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. It occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys. This, in turn, causes pain leading to patients undertaking different forms of treatments.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 41.24 Billion |
| Anticipated Forecast Value (2033) | US$ 85 Billion |
| Projected Growth Rate (2023 to 2033) | 7.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights - the market for IgA nephropathy reflected a value of 4.8% during the historical period, 2017 to 2022.
The increasing cases of COVID-19 have a direct correlation with the growth of kidney-related diseases. For instance, as per a report published in 2021, titled, "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," 4-37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an incidence of 50% among hospitalized COVID-19 patients. Thus, it has been found that the COVID-19 virus is having an impact on the kidney of patients, which in turn, is expected to increase the burden of kidney disorders in the near future and fuel the market growth.
The major factors for the growth of the IgA nephropathy market include the increasing incidence of chronic kidney diseases, technological advancements in diagnostic tests for kidney diseases, and the increasing need for early detection. Thus, the market for IgA nephropathy is expected to register a CAGR of 7.5% in the forecast period 2023 to 2033.
Conventional treatments and approval of medication favoring the growth of the market
Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers), to manage symptoms like high blood pressure, etc. Other treatments include corticosteroids, to slow the progression of the disease, and other immunosuppressants like MMF, cyclophosphamide, etc.
TARPEYO (budesonide) delayed-release capsules are the first and only FDA-approved drug for the treatment of IgAN. It is indicated for IgAN patients, who are at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. It was approved by the US FDA in December 2021, under an accelerated approval pathway, recognizing the urgent need for safe and efficacious therapies.
The availability of therapeutic treatments creates lucrative opportunities for the IgA nephropathy market
Tarpeyo: Calliditas Therapeutics AB
Tarpeyo (developed under the project name Nefecon) is a patented oral formulation of a potent and well-known active substance- budesonide for targeted release. The formulation is designed to deliver the drug to the Peyer’s patch region of the lower small intestine, where the disease originates, as per the predominant pathogenesis models. Tarpeyo is derived from the TARGIT technology, which allows the substance to pass through the stomach and intestine without being absorbed and released in a pulse-like fashion only when it reaches the lower small intestine.
In addition to its potent local effect, another advantage of using this active substance is its very low bioavailability, i.e., around 90% of it is inactivated in the liver before it reaches systemic circulation. This means that a high concentration can be applied locally where needed but with only very limited systemic exposure and side effects.
Sparsentan: Travere Therapeutics, Inc
Spartan is a first-in-class, orally active, single-molecule that functions as a high-affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors which are associated with kidney disease progression.
Endothelin I and angiotensin II lead to a decline in kidney function by contributing to inflammation and fibrosis in the kidney, changes to the shape of podocytes, podocyte loss, and increased permeability of the glomerular filtration barrier. Endothelin I and angiotensin II are also vasoconstrictive, meaning they cause a narrowing of blood vessels and an increase in pressure in the glomeruli.
Reimbursement of treatments propelling the growth of the IgA nephropathy market
Proactively approaching reimbursement can induce a positive impact both during the early stages of product development and well after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select markets with better market access can be a critical business and price strategy.
To assist patients and their healthcare providers who prescribe Tarpeyo, Calliditas has launched a comprehensive patient support program - Tarpeyo Touchpoints. It is a full-service patient and provider support program designed to accelerate and streamline access to Tarpeyo. It utilizes biologics by McKesson’s Pharmacy Elite model integrated hub and exclusive specialty pharmacy under one roof and is staffed by care navigators and a designated rare pod team (nurses, pharmacists, fulfillment, and distribution team).
Principal Consultant
Ignorance towards kidney diseases affecting IgA nephropathy market growth
Although the number of people suffering from kidney diseases is high, the unavailability of exact treatment to cure IgA nephropathy is derailing the progress of the market. In addition, a lack of awareness of kidney diseases and ignorance is severely hindering the growth of the market. In certain cases, the time taken for approval for medications is too long. This, in turn, is affecting the growth of the IgA nephropathy market.
Rising awareness of disease and treatment bolstering the market for IgA nephropathy market in North America
In the coming years, the IgAN market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators, for innovative first-in-class curative drugs, as there were no approved therapies until recently and likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence IgAN R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Major players are involved in developing therapies for IgAN. The launch of emerging therapies will significantly impact the IgAN market. Thus, North America is expected to possess a 40% market share in the IgA nephropathy market in 2023.
Lifestyle changes and sedentary lifestyles contributing to the IgA neuropathy market in the Asia Pacific
The major factors driving the growth of the market in the Asia region are the rising number of kidney cancer cases and increased R&D expenditure of pharmaceutical companies. The major countries contributing to kidney cancer cases in Asia are China and Japan. These countries were among the highest cases of kidney cancer worldwide. Furthermore, according to the International Agency for Research on Cancer, in 2018, there were about 148,947 new kidney cancer cases and the mortality was approximately 79,149 cases in Asia.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Asia-Pacific kidney cancer therapeutics & diagnostics market is expected to have significant growth over the forecast period. Owing to the aforementioned reasons, Asia Pacific is expected to possess a 35% market share for the IgA Neuropathy market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Initiatives by healthcare organizations spurring dependency on hospitals
Owing to the surge in hospitalization, doctors require diagnostic interpretation for further treatment. Usually, diagnostic centers function in association with hospitals; hence, hospitals have their diagnostic setup. Moreover, the ongoing development of healthcare infrastructure is likely to enhance existing hospital facilities, expanding their services and offerings.
Thus, this expansion may boost the demand for products such as kidney function tests, thereby driving the market. In addition, favorable reimbursement scenarios and an increase in the number of initiatives being undertaken by healthcare organizations globally to promote the use of advanced diagnostic tests are also likely to propel segment growth.
Thus, the hospital’s segment is expected to hold 40% of the market share in 2023 for the IgA nephropathy market.
Frequent requirements for urine testing increase dependability on urine tests
The urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years. One of the most frequently used procedures for assessing renal function is urea quantification. Urine, plasma, and serum urea analyses are crucial clinical tests for detecting renal illness and dysfunction. For the diagnosis of pre-renal, renal, and post-renal uremia, urine tests are frequently performed in conjunction with creatinine determination tests. Furthermore, growing investments in the renal function testing industry are also anticipated to support market expansion.
For instance, in January 2020, Sweden-based Elypta AB raised seed financing of USD 7.0 million to provide the first urine test for renal cancer.
Some of the key companies in the IgA Nephropathy therapeutics market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 41.24 Billion |
| Market Value in 2033 | US$ 85 Billion |
| Growth Rate | CAGR of 7.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Region |
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
From 2017 to 2022, the IgA nephropathy market grew at a CAGR of 4.8%
The global IgA nephropathy market is expected to grow at a 7.5% CAGR from 2023 to 2033.
As of 2033, the IgA nephropathy market is expected to reach US$ 41.24 Billion
The hospital’s segment is expected to hold 40% of the market share in 2023 for the IgA nephropathy market.
The urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years
North America is expected to possess a 40% market share in the IgA nephropathy market in 2023.
Asia Pacific IgA nephropathy market size is expected to possess a 35% market share in 2023.
1. Executive Summary | IgA Nephropathy Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033 5.3.1. Iothalamate Clearance Test 5.3.2. Kidney Biopsy 5.3.3. Blood Tests 5.3.4. Urine Tests 5.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033 6.3.1. Primary 6.3.2. Secondary 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Symptoms 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Symptoms, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Symptoms, 2023 to 2033 7.3.1. Hematuria 7.3.2. Proteinuria 7.3.3. Edema 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By Symptoms, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Symptoms, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Population Type 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Population Type, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Population Type, 2023 to 2033 8.3.1. Pediatrics 8.3.2. Adults 8.4. Y-o-Y Growth Trend Analysis By Population Type, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Population Type, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 9.3.1. Oral 9.3.2. Parenteral 9.3.3. Others 9.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 10.1. Introduction / Key Findings 10.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 10.3.1. Medication 10.3.2. Statin therapy 10.3.3. Omega-3 fatty acids 10.3.4. Angiotensin-converting enzyme (ACE) inhibitors 10.3.5. Angiotensin receptor blockers (ARBs) 10.3.6. Diuretics 10.3.7. Immunosuppressants 10.3.8. Kidney Transplantation 10.3.9. Others 10.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 10.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users 11.1. Introduction / Key Findings 11.2. Historical Market Size Value (US$ Million) Analysis By End-Users, 2018 to 2022 11.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Users, 2023 to 2033 11.3.1. Hospitals 11.3.2. Specialty Clinics 11.3.3. Homecare 11.3.4. Others 11.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022 11.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 12.1. Introduction 12.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 12.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. South Asia & Pacific 12.3.5. East Asia 12.3.6. Middle East & Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. The US 13.2.1.2. Canada 13.2.2. By Diagnosis 13.2.3. By Disease Type 13.2.4. By Symptoms 13.2.5. By Population Type 13.2.6. By Route of Administration 13.2.7. By Treatment 13.2.8. By End-Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Diagnosis 13.3.3. By Disease Type 13.3.4. By Symptoms 13.3.5. By Population Type 13.3.6. By Route of Administration 13.3.7. By Treatment 13.3.8. By End-Users 13.4. Key Takeaways 14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Brazil 14.2.1.2. Mexico 14.2.1.3. Rest of Latin America 14.2.2. By Diagnosis 14.2.3. By Disease Type 14.2.4. By Symptoms 14.2.5. By Population Type 14.2.6. By Route of Administration 14.2.7. By Treatment 14.2.8. By End-Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Diagnosis 14.3.3. By Disease Type 14.3.4. By Symptoms 14.3.5. By Population Type 14.3.6. By Route of Administration 14.3.7. By Treatment 14.3.8. By End-Users 14.4. Key Takeaways 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Germany 15.2.1.2. The UK 15.2.1.3. France 15.2.1.4. Spain 15.2.1.5. Italy 15.2.1.6. Rest of Europe 15.2.2. By Diagnosis 15.2.3. By Disease Type 15.2.4. By Symptoms 15.2.5. By Population Type 15.2.6. By Route of Administration 15.2.7. By Treatment 15.2.8. By End-Users 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Diagnosis 15.3.3. By Disease Type 15.3.4. By Symptoms 15.3.5. By Population Type 15.3.6. By Route of Administration 15.3.7. By Treatment 15.3.8. By End-Users 15.4. Key Takeaways 16. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. India 16.2.1.2. Malaysia 16.2.1.3. Singapore 16.2.1.4. Thailand 16.2.1.5. Australia 16.2.1.6. New Zealand 16.2.1.7. Rest of South Asia & Pacific 16.2.2. By Diagnosis 16.2.3. By Disease Type 16.2.4. By Symptoms 16.2.5. By Population Type 16.2.6. By Route of Administration 16.2.7. By Treatment 16.2.8. By End-Users 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Diagnosis 16.3.3. By Disease Type 16.3.4. By Symptoms 16.3.5. By Population Type 16.3.6. By Route of Administration 16.3.7. By Treatment 16.3.8. By End-Users 16.4. Key Takeaways 17. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. China 17.2.1.2. Japan 17.2.1.3. South Korea 17.2.2. By Diagnosis 17.2.3. By Disease Type 17.2.4. By Symptoms 17.2.5. By Population Type 17.2.6. By Route of Administration 17.2.7. By Treatment 17.2.8. By End-Users 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Diagnosis 17.3.3. By Disease Type 17.3.4. By Symptoms 17.3.5. By Population Type 17.3.6. By Route of Administration 17.3.7. By Treatment 17.3.8. By End-Users 17.4. Key Takeaways 18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 18.2.1. By Country 18.2.1.1. GCC Countries 18.2.1.2. South Africa 18.2.1.3. Israel 18.2.1.4. Rest of MEA 18.2.2. By Diagnosis 18.2.3. By Disease Type 18.2.4. By Symptoms 18.2.5. By Population Type 18.2.6. By Route of Administration 18.2.7. By Treatment 18.2.8. By End-Users 18.3. Market Attractiveness Analysis 18.3.1. By Country 18.3.2. By Diagnosis 18.3.3. By Disease Type 18.3.4. By Symptoms 18.3.5. By Population Type 18.3.6. By Route of Administration 18.3.7. By Treatment 18.3.8. By End-Users 18.4. Key Takeaways 19. Key Countries Market Analysis 19.1. The US 19.1.1. Pricing Analysis 19.1.2. Market Share Analysis, 2022 19.1.2.1. By Diagnosis 19.1.2.2. By Disease Type 19.1.2.3. By Symptoms 19.1.2.4. By Population Type 19.1.2.5. By Route of Administration 19.1.2.6. By Treatment 19.1.2.7. By End-Users 19.2. Canada 19.2.1. Pricing Analysis 19.2.2. Market Share Analysis, 2022 19.2.2.1. By Diagnosis 19.2.2.2. By Disease Type 19.2.2.3. By Symptoms 19.2.2.4. By Population Type 19.2.2.5. By Route of Administration 19.2.2.6. By Treatment 19.2.2.7. By End-Users 19.3. Brazil 19.3.1. Pricing Analysis 19.3.2. Market Share Analysis, 2022 19.3.2.1. By Diagnosis 19.3.2.2. By Disease Type 19.3.2.3. By Symptoms 19.3.2.4. By Population Type 19.3.2.5. By Route of Administration 19.3.2.6. By Treatment 19.3.2.7. By End-Users 19.4. Mexico 19.4.1. Pricing Analysis 19.4.2. Market Share Analysis, 2022 19.4.2.1. By Diagnosis 19.4.2.2. By Disease Type 19.4.2.3. By Symptoms 19.4.2.4. By Population Type 19.4.2.5. By Route of Administration 19.4.2.6. By Treatment 19.4.2.7. By End-Users 19.5. Germany 19.5.1. Pricing Analysis 19.5.2. Market Share Analysis, 2022 19.5.2.1. By Diagnosis 19.5.2.2. By Disease Type 19.5.2.3. By Symptoms 19.5.2.4. By Population Type 19.5.2.5. By Route of Administration 19.5.2.6. By Treatment 19.5.2.7. By End-Users 19.6. The UK 19.6.1. Pricing Analysis 19.6.2. Market Share Analysis, 2022 19.6.2.1. By Diagnosis 19.6.2.2. By Disease Type 19.6.2.3. By Symptoms 19.6.2.4. By Population Type 19.6.2.5. By Route of Administration 19.6.2.6. By Treatment 19.6.2.7. By End-Users 19.7. France 19.7.1. Pricing Analysis 19.7.2. Market Share Analysis, 2022 19.7.2.1. By Diagnosis 19.7.2.2. By Disease Type 19.7.2.3. By Symptoms 19.7.2.4. By Population Type 19.7.2.5. By Route of Administration 19.7.2.6. By Treatment 19.7.2.7. By End-Users 19.8. Spain 19.8.1. Pricing Analysis 19.8.2. Market Share Analysis, 2022 19.8.2.1. By Diagnosis 19.8.2.2. By Disease Type 19.8.2.3. By Symptoms 19.8.2.4. By Population Type 19.8.2.5. By Route of Administration 19.8.2.6. By Treatment 19.8.2.7. By End-Users 19.9. Italy 19.9.1. Pricing Analysis 19.9.2. Market Share Analysis, 2022 19.9.2.1. By Diagnosis 19.9.2.2. By Disease Type 19.9.2.3. By Symptoms 19.9.2.4. By Population Type 19.9.2.5. By Route of Administration 19.9.2.6. By Treatment 19.9.2.7. By End-Users 19.10. India 19.10.1. Pricing Analysis 19.10.2. Market Share Analysis, 2022 19.10.2.1. By Diagnosis 19.10.2.2. By Disease Type 19.10.2.3. By Symptoms 19.10.2.4. By Population Type 19.10.2.5. By Route of Administration 19.10.2.6. By Treatment 19.10.2.7. By End-Users 19.11. Malaysia 19.11.1. Pricing Analysis 19.11.2. Market Share Analysis, 2022 19.11.2.1. By Diagnosis 19.11.2.2. By Disease Type 19.11.2.3. By Symptoms 19.11.2.4. By Population Type 19.11.2.5. By Route of Administration 19.11.2.6. By Treatment 19.11.2.7. By End-Users 19.12. Singapore 19.12.1. Pricing Analysis 19.12.2. Market Share Analysis, 2022 19.12.2.1. By Diagnosis 19.12.2.2. By Disease Type 19.12.2.3. By Symptoms 19.12.2.4. By Population Type 19.12.2.5. By Route of Administration 19.12.2.6. By Treatment 19.12.2.7. By End-Users 19.13. Thailand 19.13.1. Pricing Analysis 19.13.2. Market Share Analysis, 2022 19.13.2.1. By Diagnosis 19.13.2.2. By Disease Type 19.13.2.3. By Symptoms 19.13.2.4. By Population Type 19.13.2.5. By Route of Administration 19.13.2.6. By Treatment 19.13.2.7. By End-Users 19.14. Australia 19.14.1. Pricing Analysis 19.14.2. Market Share Analysis, 2022 19.14.2.1. By Diagnosis 19.14.2.2. By Disease Type 19.14.2.3. By Symptoms 19.14.2.4. By Population Type 19.14.2.5. By Route of Administration 19.14.2.6. By Treatment 19.14.2.7. By End-Users 19.15. New Zealand 19.15.1. Pricing Analysis 19.15.2. Market Share Analysis, 2022 19.15.2.1. By Diagnosis 19.15.2.2. By Disease Type 19.15.2.3. By Symptoms 19.15.2.4. By Population Type 19.15.2.5. By Route of Administration 19.15.2.6. By Treatment 19.15.2.7. By End-Users 19.16. China 19.16.1. Pricing Analysis 19.16.2. Market Share Analysis, 2022 19.16.2.1. By Diagnosis 19.16.2.2. By Disease Type 19.16.2.3. By Symptoms 19.16.2.4. By Population Type 19.16.2.5. By Route of Administration 19.16.2.6. By Treatment 19.16.2.7. By End-Users 19.17. Japan 19.17.1. Pricing Analysis 19.17.2. Market Share Analysis, 2022 19.17.2.1. By Diagnosis 19.17.2.2. By Disease Type 19.17.2.3. By Symptoms 19.17.2.4. By Population Type 19.17.2.5. By Route of Administration 19.17.2.6. By Treatment 19.17.2.7. By End-Users 19.18. South Korea 19.18.1. Pricing Analysis 19.18.2. Market Share Analysis, 2022 19.18.2.1. By Diagnosis 19.18.2.2. By Disease Type 19.18.2.3. By Symptoms 19.18.2.4. By Population Type 19.18.2.5. By Route of Administration 19.18.2.6. By Treatment 19.18.2.7. By End-Users 19.19. GCC Countries 19.19.1. Pricing Analysis 19.19.2. Market Share Analysis, 2022 19.19.2.1. By Diagnosis 19.19.2.2. By Disease Type 19.19.2.3. By Symptoms 19.19.2.4. By Population Type 19.19.2.5. By Route of Administration 19.19.2.6. By Treatment 19.19.2.7. By End-Users 19.20. South Africa 19.20.1. Pricing Analysis 19.20.2. Market Share Analysis, 2022 19.20.2.1. By Diagnosis 19.20.2.2. By Disease Type 19.20.2.3. By Symptoms 19.20.2.4. By Population Type 19.20.2.5. By Route of Administration 19.20.2.6. By Treatment 19.20.2.7. By End-Users 19.21. Israel 19.21.1. Pricing Analysis 19.21.2. Market Share Analysis, 2022 19.21.2.1. By Diagnosis 19.21.2.2. By Disease Type 19.21.2.3. By Symptoms 19.21.2.4. By Population Type 19.21.2.5. By Route of Administration 19.21.2.6. By Treatment 19.21.2.7. By End-Users 20. Market Structure Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Market Share Analysis of Top Players 20.3.1. By Regional 20.3.2. By Diagnosis 20.3.3. By Disease Type 20.3.4. By Symptoms 20.3.5. By Population Type 20.3.6. By Route of Administration 20.3.7. By Treatment 20.3.8. By End-Users 21. Competition Analysis 21.1. Competition Deep Dive 21.1.1. Calliditas Therapeutics AB 21.1.1.1. Overview 21.1.1.2. Product Portfolio 21.1.1.3. Profitability by Market Segments 21.1.1.4. Sales Footprint 21.1.1.5. Strategy Overview 21.1.1.5.1. Marketing Strategy 21.1.2. Travere Therapeutics, Inc. 21.1.2.1. Overview 21.1.2.2. Product Portfolio 21.1.2.3. Profitability by Market Segments 21.1.2.4. Sales Footprint 21.1.2.5. Strategy Overview 21.1.2.5.1. Marketing Strategy 21.1.3. Omeros Corporation 21.1.3.1. Overview 21.1.3.2. Product Portfolio 21.1.3.3. Profitability by Market Segments 21.1.3.4. Sales Footprint 21.1.3.5. Strategy Overview 21.1.3.5.1. Marketing Strategy 21.1.4. Novartis Pharmaceuticals 21.1.4.1. Overview 21.1.4.2. Product Portfolio 21.1.4.3. Profitability by Market Segments 21.1.4.4. Sales Footprint 21.1.4.5. Strategy Overview 21.1.4.5.1. Marketing Strategy 21.1.5. Chinook Therapeutics, Inc. 21.1.5.1. Overview 21.1.5.2. Product Portfolio 21.1.5.3. Profitability by Market Segments 21.1.5.4. Sales Footprint 21.1.5.5. Strategy Overview 21.1.5.5.1. Marketing Strategy 21.1.6. Vera Therapeutics, Inc. 21.1.6.1. Overview 21.1.6.2. Product Portfolio 21.1.6.3. Profitability by Market Segments 21.1.6.4. Sales Footprint 21.1.6.5. Strategy Overview 21.1.6.5.1. Marketing Strategy 21.1.7. Otsuka Pharmaceutical 21.1.7.1. Overview 21.1.7.2. Product Portfolio 21.1.7.3. Profitability by Market Segments 21.1.7.4. Sales Footprint 21.1.7.5. Strategy Overview 21.1.7.5.1. Marketing Strategy 21.1.8. Alembic Pharmaceuticals Limited 21.1.8.1. Overview 21.1.8.2. Product Portfolio 21.1.8.3. Profitability by Market Segments 21.1.8.4. Sales Footprint 21.1.8.5. Strategy Overview 21.1.8.5.1. Marketing Strategy 21.1.9. Teva Pharmaceutical Industries Ltd. 21.1.9.1. Overview 21.1.9.2. Product Portfolio 21.1.9.3. Profitability by Market Segments 21.1.9.4. Sales Footprint 21.1.9.5. Strategy Overview 21.1.9.5.1. Marketing Strategy 21.1.10. Johnson & Johnson Private Limited 21.1.10.1. Overview 21.1.10.2. Product Portfolio 21.1.10.3. Profitability by Market Segments 21.1.10.4. Sales Footprint 21.1.10.5. Strategy Overview 21.1.10.5.1. Marketing Strategy 22. Assumptions & Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
IgA Nephropathy Market
